Artificial thymic organoids represent a reliable tool to study T-cell differentiation in patients with severe T-cell lymphopenia.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
23 06 2020
23 06 2020
Historique:
received:
24
02
2020
accepted:
12
05
2020
entrez:
20
6
2020
pubmed:
20
6
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
The study of early T-cell development in humans is challenging because of limited availability of thymic samples and the limitations of in vitro T-cell differentiation assays. We used an artificial thymic organoid (ATO) platform generated by aggregating a DLL4-expressing stromal cell line (MS5-hDLL4) with CD34+ cells isolated from bone marrow or mobilized peripheral blood to study T-cell development from CD34+ cells of patients carrying hematopoietic intrinsic or thymic defects that cause T-cell lymphopenia. We found that AK2 deficiency is associated with decreased cell viability and an early block in T-cell development. We observed a similar defect in a patient carrying a null IL2RG mutation. In contrast, CD34+ cells from a patient carrying a missense IL2RG mutation reached full T-cell maturation, although cell numbers were significantly lower than in controls. CD34+ cells from patients carrying RAG mutations were able to differentiate to CD4+CD8+ cells, but not to CD3+TCRαβ+ cells. Finally, normal T-cell differentiation was observed in a patient with complete DiGeorge syndrome, consistent with the extra-hematopoietic nature of the defect. The ATO system may help determine whether T-cell deficiency reflects hematopoietic or thymic intrinsic abnormalities and define the exact stage at which T-cell differentiation is blocked.
Identifiants
pubmed: 32556283
pii: S2473-9529(20)31240-4
doi: 10.1182/bloodadvances.2020001730
pmc: PMC7322962
doi:
Substances chimiques
Antigens, CD34
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2611-2616Subventions
Organisme : NCI NIH HHS
ID : P30 CA016042
Pays : United States
Organisme : NIAID NIH HHS
ID : R13 AI094943
Pays : United States
Organisme : NIAID NIH HHS
ID : U54 AI082973
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA AI001222
Pays : United States
Commentaires et corrections
Type : ErratumIn
Références
Cell. 1993 Apr 9;73(1):147-57
pubmed: 8462096
J Exp Med. 2005 Jun 6;201(11):1715-23
pubmed: 15928199
Blood. 2018 Oct 25;132(17):1737-1749
pubmed: 30154114
Blood. 2014 Jan 9;123(2):281-9
pubmed: 24144642
Nat Methods. 2017 May;14(5):521-530
pubmed: 28369043
Biochem Pharmacol. 2003 Oct 15;66(8):1595-9
pubmed: 14555239
Science. 2020 Feb 21;367(6480):
pubmed: 32079746
Cell. 1992 Mar 6;68(5):855-67
pubmed: 1547487
Nat Genet. 2009 Jan;41(1):106-11
pubmed: 19043416
Nat Genet. 2009 Jan;41(1):101-5
pubmed: 19043417
Cell Death Dis. 2015 Aug 13;6:e1856
pubmed: 26270350
J Immunol. 2005 Feb 1;174(3):1213-21
pubmed: 15661875
J Allergy Clin Immunol. 2016 Feb;137(2):517-526.e3
pubmed: 26441229
Cell. 1992 Mar 6;68(5):869-77
pubmed: 1547488
Blood. 2016 Aug 11;128(6):783-93
pubmed: 27301863
Blood Adv. 2020 Jun 23;4(12):2606-2610
pubmed: 32556280
J Exp Med. 2015 Jul 27;212(8):1185-202
pubmed: 26150473
PLoS One. 2015 Apr 29;10(4):e0125373
pubmed: 25923356